ÉúÎï½ç¿¸°Ñ×Ó-ÍâÃÚÌåËÞÊÀ½ñÉú¼°Ó¦ÓÃÔ¶¾°
1¡¢ÍâÃÚÌåµÄËÞÊÀ½ñÉú
1983ÄêÔÚ²¸È鶯Îïϸ°ûÖÐÊ״η¢Ã÷¶¯ÎïÍâÃÚÌ壬£¬£¬£¬£¬¸Õ×îÏȲ¢Î´»ñµÃÖØÊÓ£¬£¬£¬£¬£¬ÉõÖÁÒÔΪËüÊÇ“ÉøÍ¸·ÏÎ¬£¬£¬£¬£¬µ«Ëæ×ÅÑо¿µÄÉîÈ룬£¬£¬£¬£¬¿ÆÑÐÕßÖð½¥·¢Ã÷£¬£¬£¬£¬£¬ËüССµÄÉíÇûÈ´Ô̺¬×Å´ó´óµÄÄÜÁ¿¡£¡£¡£¡£¡£½üЩÄ꣬£¬£¬£¬£¬ÍâÃÚÌå±»¸¶ÓëÁËÖÖÖÖ±êÇ©£ºÒ½Ñ§ÃÀÈÝ£¬£¬£¬£¬£¬Ò½Ñ§Õï¶Ï£¬£¬£¬£¬£¬Ò½Ñ§ÓÃÒ©£¬£¬£¬£¬£¬È«Çò¿ÆÑÐÍŶӷ׷×Ôú¶Ñ´ËÁìÓò£¬£¬£¬£¬£¬ÓйØÍâÃÚÌåÑо¿Æ«ÏòµÄÎÄÕÂÂ½Ðø½ÒÏþÔÚScience¡¢NatureµÈ¸÷´ó¶¥¼¶ÆÚ¿¯ÉÏ¡£¡£¡£¡£¡£È«ÇòÍâÃÚÌåÑо¿Êг¡¹æÄ£Ò»Á¬ÔöÌí£¬£¬£¬£¬£¬2024ÄêÈ«ÇòÍâÃÚÌåÑо¿Êг¡¹æÄ£Ô¤¼Æ´ï1.9ÒÚÃÀÔª£¬£¬£¬£¬£¬²¢Ô¤¼Æ½«ÒÔ31.5%µÄ¸´ºÏÄêÔöÌíÂÊÔöÌí¡£¡£¡£¡£¡£ÕâÒ»ÔöÌíÖ÷ÒªµÃÒæÓÚ±±ÃÀµØÇøÍêÉÆµÄÒ½ÁƱ£½¡»ù´¡ÉèÊ©¡¢ÓÐÓõĹ«¹²¹æÔòÒÔ¼°ÊýÄ¿¿É¹ÛµÄ¿ç¹úÆóÒµµÈÒòËØµÄÍÆ¶¯¡£¡£¡£¡£¡£
ÍâÃÚÌåÓÐÍû³ÉΪδÀ´Ò½Ñ§Éú³¤µÄÏÂÒ»¸ö·çÏò±ê¡£¡£¡£¡£¡£

ͼ1.ÍâÃÚÌåÎÄÏ×½ÒÏþͳ¼Æ£¨Êý¾ÝȪԴpubmed£©
ÍâÃÚÌå¿ÉÒÔÖ±½Ó·´Ó¦×é֯ϸ°ûµÄת±ä£»£»£»£»£»£»°üÀ¨×ðÁú¿Ê±ÖÊ£¬£¬£¬£¬£¬RNA£¬£¬£¬£¬£¬Ö¬ÖʵÈÐÅÏ¢£¬£¬£¬£¬£¬Í¬Ê±£¬£¬£¬£¬£¬¿ÉÒÔÕ¹ÏÖ¸ü¶àµÄ·Ö×Óת±ä£»£»£»£»£»£»Ö¬ÖÊË«·Ö×Ó²ã°ü¹üÄÚÈÝÎ£¬£¬£¬£¬ÈÃÆäÃâÊÜϸ°ûÍâø½µ½â£»£»£»£»£»£»²¢ÇÒ£¬£¬£¬£¬£¬ÍâÃÚÌåÏÕЩ±£´æÓÚËùÓеÄÌåÒºÖУ¬£¬£¬£¬£¬±ãÓÚ»ñÈ¡£¡£¡£¡£¡£»£»£»£»£»£»ËäȻֻÓÐ100¶ànm£¬£¬£¬£¬£¬µ«ËüЯ´øÁ˳¬µÈ¶àµÄÐÅÏ¢£¬£¬£¬£¬£¬ÏÖÔÚÑо¿·¢Ã÷£¬£¬£¬£¬£¬ÍâÃÚÌå¿ÉÒÔЯ´ø×Å4563ÖÖ×ðÁú¿Ê±ÖÊ£¬£¬£¬£¬£¬1639ÖÖmRNAºÍ764ÖÖmRNAs£¬£¬£¬£¬£¬194ÖÖÖ¬ÀàºÍ·´Ó¦Ï¸°ûÆðÔ´ÀàÐ͵Ĵúл²úÆ·¡£¡£¡£¡£¡£ÃÀ¹úNIH×ÊÖúÁËÐí¶à·ÇÖ×ÁöÁìÓòµÄÍâÃÚÌå±ê¼ÇÎïÑо¿£¬£¬£¬£¬£¬³ýÁËÖ×Áö£¬£¬£¬£¬£¬ÍâÃÚÌå×÷ΪÆäËû¼²²¡±ê¼ÇÎïµÄÑо¿Ò²Ô½À´Ô½¶à£¬£¬£¬£¬£¬°üÀ¨ÌÇÄò²¡¡¢¸Î²¡¡¢²¡¶¾Ñ¬È¾¡¢ºôÎüϵͳ¼²²¡¡¢ÈÑÉïÏà¹Ø¼²²¡¡¢Éñ¾¼²²¡¡¢ÐàÂõÒÔ¼°ÇéÐΡ¢ÎüÑÌ¡¢Ô˶¯µÈÍâ½çÒòËØµ¼ÖµĻúÌåת±äµÈ¡£¡£¡£¡£¡£

ͼ2.ÍâÃÚÌåȪԴ
2¡¢ÍâÃÚÌåÓ¦ÓÃ
£¨1£©¼²²¡ÖÎÁÆ-°¢¶û´Äº£Ä¬Ö¢
ÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½ÔºÍõ¸Õ½ÌÊÚÍŶÓÍê³É²¢Ðû²¼½ÓÄɼä³äÖʸÉϸ°ûȪԴµÄÍâÃÚÌåÅç±ÇÖÎÁư¢¶û´Äº£Ä¬²¡µÄ¹ú¼ÊÊ׸öÁÙ´²ÊÔÑ飨Clinical Trial NCT04388982£©£¬£¬£¬£¬£¬¸ÃÑо¿Ð§¹û½ÒÏþÓÚGeneral Psychiatry£¬£¬£¬£¬£¬ÂÛÎÄÎÊÌâΪ“Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer‘s disease: A phase I/II clinical trial”¡£¡£¡£¡£¡£°¢¶û´Äº£Ä¬²¡£¡£¡£¡£¡£¨Alzheimer’s disease£¬£¬£¬£¬£¬AD£©ÊÇ×î³£¼ûµÄÉñ¾ÍËÐÐÐÔ¼²²¡£¬£¬£¬£¬£¬Ò²Êdzմô×î³£¼ûµÄ²¡Òò£¬£¬£¬£¬£¬ÏÖÔÚÉÐÎÞÓÐÓõÄÖÎÓúÊֶΣ¬£¬£¬£¬£¬Ê¹Ö®³ÉΪÍþвÍíÄêÈËÉúÑÄÖÊÁ¿µÄÖØ´ó¿µ½¡É±ÊÖ¡£¡£¡£¡£¡£ÏàÖúÍŶÓǰÆÚÑо¿Åú×¢ÔÚСÊóÄ£×ÓÖУ¬£¬£¬£¬£¬À´×Ô¿µ½¡×ÔÔ¸ÕßµÄÈËÖ¬·¾ÑÜÉúµÄ¼ä³äÖʸÉϸ°ûÍâÃÚÌ壨ahaMSC-Exos£©±ÇÄÚ¸øÒ©¿É¸ÄÉÆAD²¡Àí״̬¼°¿Õ¼äÓ°Ï󡣡£¡£¡£¡£ÎªÁË̽Ë÷ahaMSC-ExosµÄÁÙ´²Ó¦Óü°ÖÎÁƵĿÉÄÜÐÔ£¬£¬£¬£¬£¬Íõ¸Õ½ÌÊÚÍŶӿªÕ¹Á˹ú¼ÊÊ׸öÍâÃÚÌåÅç±ÇÖÎÁÆADÁÙ´²ÊÔÑ飨Clinical Trial NCT04388982£©£¬£¬£¬£¬£¬ÑéÖ¤ÆäÔÚAD»¼ÕßÖÐͨ¹ý±ÇÄÚ¸øÒ©µÄÇå¾²ÐÔºÍÓÐÓÃÐÔ¡£¡£¡£¡£¡£ÕâÏîÊÔÑéÊǹú¼ÊÊ×´ÎʵÑ齫MSCsÉøÍ¸µÄÍâÃÚÌåÓ¦ÓÃÓÚÁÙ´²ÖÎÁÆAD£¬£¬£¬£¬£¬ÎªADµÄÖÎÁÆ´øÀ´ÁËÏ£Íû¡£¡£¡£¡£¡£Ð§¹ûÅú×¢£¬£¬£¬£¬£¬ÖеȼÁÁ¿×éÊÜÊÔÕßADAS-cogÆÀ·ÖÔÚµÚ12ÖÜϽµÁË2.33£¨1.19£©£¬£¬£¬£¬£¬MoCA-BÆÀ·ÖÔöÌíÁË2.38£¨0.58£©£¬£¬£¬£¬£¬Åú×¢ÈÏÖª¹¦Ð§ÓÐËù¸ÄÉÆ£¬£¬£¬£¬£¬Í¬Ê±Ò²Ö¤ÊµÎúahaMSCs-Exos¾±ÇÄÚ¸øÒ©ÖÎÁÆADÊÇÇå¾²µÄ£¬£¬£¬£¬£¬ÖÁÉÙ¿ÉÑ¡Ôñ4×10^8¼ÁÁ¿¾ÙÐиü´ó¹æÄ£µÄ¶àÖÐÐÄÁÙ´²ÊÔÑé¡£¡£¡£¡£¡£

ͼ3. ÁÙ´²ÊÔÑéµÄÑо¿Éè¼Æ
£¨2£©Õï¶ÏÁìÓò
ÍâÃÚÌåÖеÄRNA»ò×ðÁú¿Ê±ÖÊÒòËØ¿ÉÒÔ×÷ΪÐÂÐ͵ÄÉúÎï±ê¼ÇÎ£¬£¬£¬£¬ÓÃÓÚÕï¶ÏÖÖÖÖ¼²²¡¡£¡£¡£¡£¡£ÓÉÓÚÍâÃÚÌåÎȹÌЯ´øÏ¸°ûÉúÎï±ê¼ÇÎ£¬£¬£¬£¬ÇÒÒ×ÓÚÊÕÂÞ¡¢Öü´æºÍÔÚÌåÄÚÔËËÍ£¬£¬£¬£¬£¬Òò´ËÔÚ¼²²¡Õï¶Ï·½Ãæ¾ßÓÐÖØ´óDZÁ¦¡£¡£¡£¡£¡£ÊʺÏ×öÉúÎï±ê¼ÇÎï·Ö×ÓÓУºDNA£¬£¬£¬£¬£¬RNA£¬£¬£¬£¬£¬×ðÁú¿Ê±ÖÊ£¬£¬£¬£¬£¬Ö¬ÖÊ£¬£¬£¬£¬£¬ëĶΣ¬£¬£¬£¬£¬´úл²úÆ·£¬£¬£¬£¬£¬¾ÛÌǵȡ£¡£¡£¡£¡£Ç°ÆÚËѼ¯ÁÙ´²Ñù±¾µÄʱ¼äÐèÒª×¢ÖØ¼¸¸öµã£º
♦ÁÙ´²»ù±¾ÐÅÏ¢£ºÄêËê¡¢ÐÔ±ð¡¢Ãñ×å¡¢ÈÑÉï¡¢»¼²¡Ê·¡¢ÓÃÒ©Ê·¡¢ÊÇ·ñ·þÓÿ¹Äý¼Á¡¢ÆäËûÑо¿Ïà¹ØÏîÄ¿£»£»£»£»£»£»
♦ÊÕÂÞÐÅÏ¢£º»ñȡʱ¼ä¡¢ÊÇ·ñÈÜѪ¡¢²ÉѪºó´¦Öóͷ£ËÞÊÀ´æÎ¶Èʱ¼ä¡¢²ÉѪ¹ÜÀàÐÍ¡¢ÕëÍ·ÀàÐÍ£»£»£»£»£»£»´¦Öóͷ£ÉúÑÄÐÅÏ¢
♦±ê±¾ÀàÐÍ£ºÊÇ·ñÓжàÖÖÌåÒºÅä¶Ô±ê±¾¡¢ÀëÐÄÁ¦¡¢ÀëÐÄʱ¼ä¡¢ÍøÂçÉÏÇåµÄÌå»ý¡¢¶³ÈÚ´ÎÊý¡¢ºã¾ÃÉúÑÄζȡ£¡£¡£¡£¡£
ÓÅÊÆ£º
£¨1£©ÎÞ´´£¬£¬£¬£¬£¬ÓÐÍû×÷Ϊ²¡Çé¼à²â±ê¼ÇÎ£»£»£»£»£»
£¨2£©¸üÖÜÈ«µÄ·´Ó¦Ö×ÁöÇéÐΣ»£»£»£»£»£»
£¨3£©Ñ¸ËٶȸßÇÒѪÇå×ÌÈŽÏÉÙ£»£»£»£»£»£»
£¨4£©±£´æÓÚ¶àÖÖÌåÒºÖУ»£»£»£»£»£»
£¨5£©Ö¬ÖÊË«²ãĤ±£»£»£»£»£»£»¤×÷Ó㬣¬£¬£¬£¬·Ö×Ó¸üÎȹ̣¬£¬£¬£¬£¬
£¨6£©Ò×ÓÚÉúÑÄ¡£¡£¡£¡£¡£

ͼ4.ÍâÃÚÌå×÷ΪÉúÎï±ê¼ÇÎïÉêÇëµÄרÀû£¨²¿·Öͳ¼Æ£©
£¨3£©Ò©ÎïµÝËÍ
ÍâÃÚÌå¾ßÓÐ×ÔȻϸ°ûĤ°ü¹üµÄÌØÕ÷£¬£¬£¬£¬£¬¿ÉÒÔÓÃÓÚÒ©ÎïµÝËÍ¡£¡£¡£¡£¡£ÕâÖÖµÝËÍ·½·¨¿ÉÒÔÌá¸ßÒ©ÎïµÄÎȹÌÐÔ¡¢ÉúÎï¿ÉʹÓÃÐԺͰÐÏò×÷Ó㬣¬£¬£¬£¬Í¬Ê±ïÔ̶¾¸±×÷Óᣡ£¡£¡£¡£ÕâΪ¿ª·¢ÐÂÐÍÒ©ÎïµÝËÍϵͳÌṩÁËÐÂ˼Ð÷¡£¡£¡£¡£¡£ÄÚÈÝÎï¸ºÔØÊÇÈÃÍâÃÚÌå×°ÔØ×ðÁú¿Ê±ÖÊ¡¢ºËËᡢС·Ö×Ó»¯ºÏÎïµÈÒ©Îï¡£¡£¡£¡£¡£¸ºÔØ·½·¨Ö÷ÒªÊÇ×Ô¶¯ÔËÊäºÍ±»¶¯À©É¢¡£¡£¡£¡£¡£±»¶¯Á¬ÏµÏà¶Ô¼òÆÓ²¢ÇÒ¿ÉÒÔ¼á³ÖÍâÃÚÌåµÄÐÎ̬£¬£¬£¬£¬£¬µ«×°ÔØÐ§Âʽϵͣ¬£¬£¬£¬£¬Ö÷Ҫͨ¹ýŨ¶ÈÌݶȲҩÎïÀ©É¢µ½ÍâÃÚÌåÄÚ¡£¡£¡£¡£¡£×Ô¶¯Á¬Ïµ·½·¨ÐèÒªÔÝÊ±ÆÆËðϸ°ûĤ£¬£¬£¬£¬£¬Ê¹Ò©ÎïºÜÈÝÒ×½øÈëÍâÃÚÌåµÄÄÚ²¿¡£¡£¡£¡£¡£ÔÚÒ©ÎïÀ©É¢ºó£¬£¬£¬£¬£¬ÍâÃÚÌåµÄĤ֨лָ´£¬£¬£¬£¬£¬³£ÓÃÒªÁìÊǵ紩¿×ºÍ³¬ÉùÒªÁì¡£¡£¡£¡£¡£ÏÖÔÚÍâÃÚÌåÒ©Îï×°ÔØ³ýÁ˲¸È鶯Îïϸ°ûȪԴµÄÍâÃÚÌåÖ®Í⣬£¬£¬£¬£¬Ö²ÎïȪԴÍâÃÚÌåÒ²×îÏÈÖð²½±»ÉîÈëÑо¿¡£¡£¡£¡£¡£
Ö²ÎïÍâÃÚÌåÑùÄÉÃ×ÄÒÅÝ£¨plant exosome-like nanovesicles, PELNVs£©¸»º¬ÖÖÖÖ¾ßÓÐÉúÎï»îÐÔµÄÖ¬ÖÊ¡¢×ðÁú¿Ê±ÖÊ¡¢RNAµÈÒòËØ£¬£¬£¬£¬£¬ÊÇ×ÔÈ»µÄÄÉÃ×ÖÆ¼Á£¬£¬£¬£¬£¬Òò´Ë¿É×÷ΪµÍ¶¾µÄÄ˽×ÔØÌåʵÏÖ¶ÔÍâÔ´ÐÔÒ©Îï·Ö×ӵĵÝËÍ¡£¡£¡£¡£¡£Ó벸È鶯ÎïȪԴºÍÈ˹¤ºÏ³ÉµÄÄÉÃ×ÄÒÅÝÏà±È£¬£¬£¬£¬£¬»ùÓÚPELNVµÄÒ©ÎïµÝËÍÄÉÃׯ½Ì¨ÔÚÉúÎïÏàÈÝÐÔ¡¢ÎȹÌÐÔ¡¢ÌåÄÚÂþÑÜ¡¢ÑÓÉì°ëË¥ÆÚºÍϸ°ûÄÚ»¯µÈ·½Ãæ¶¼ÌåÏÖ³öÏÔÖøµÄÓÅÊÆ¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬PELNVs»¹¾ßÓÐÌå»ýС¡¢×éÖ¯´©Í¸ÐÔÇ¿µÈÓŵ㣬£¬£¬£¬£¬ÔÚ²î±ðµÄËá¼î¶ÈºÍζÈ϶¼ÄÜά³Ö½ÏºÃµÄÀí»¯ÎȹÌÐÔ¡£¡£¡£¡£¡£ÓÉÓÚÖ²ÎïÖÊÁÏȪԴÆÕ±é£¬£¬£¬£¬£¬ÇÒÖÊÁϱ¾Ç®µÍÁ®£¬£¬£¬£¬£¬Í¨¹ý¶à²½²îËÙÀëÐÄ·¨ÁªºÏÕáÌÇÃܶÈÌݶÈÀëÐÄ·¨»ñµÃµÄPELNVsµÄ²úÁ¿½Ï¸ß£¬£¬£¬£¬£¬ ÕâºÜÊÇÓÐÀûÓÚPELNVsÔÚÓ¦ÓÃÖеĴó¹æÄ£ÅúÁ¿Éú²ú£¬£¬£¬£¬£¬Í³¼ÆÊý¾ÝÏÔʾһÑùƽ³£100g Ö²ÎïÖÊÁÏ¿ÉÒÔÌáÈ¡320-450 mgµÄPELNVs ¡£¡£¡£¡£¡£ËùÓÐÕâÐ©ÌØÕ÷¶¼Ê¹µÃPELNVs³ÉΪ¾Æ¤µÝËÍ¡¢°ÐÏò¸øÒ©¡¢»ùÒòת´ïµÈÒ©ÎïµÝËÍÖнÏÀíÏëµÄÔØÌåÑ¡Ôñ£¬£¬£¬£¬£¬¾ßÓÐÁÉÀ«µÄÓ¦ÓÃÔ¶¾°¡£¡£¡£¡£¡£
³ÂÕñÍŶÓÔÚÆÚ¿¯¡¶Journal of Nanobiotechnology¡·½ÒÏþÁËһƪÃûΪ“Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review”µÄÎÄÕ£¬£¬£¬£¬£¬×÷Õß×ܽáÁËÄ¿½ñ¹¤³ÌÍâÃÚÌåºÍÆÀ¹ÀÆäÒ©ÎïµÝËÍ×÷ÓõÄÒªÁ죬£¬£¬£¬£¬²¢ÑÏ¿áÉó²éÁËÄ¿½ñÆÀ¹ÀÍâÃÚÌåÒ©Îï¸ºÔØºÍÊͷŶ¯Á¦Ñ§¡¢Ï¸°û°ÐÏò¡¢ÉúÎïÂþÑÜ¡¢Ò©´ú¶¯Á¦Ñ§ºÍÖÎÁÆÐ§¹ûµÄ¼¼Êõ£¬£¬£¬£¬£¬²¢×ÛºÏÁËÍâÃÚÌ幤³ÌºÍÒ©ÎïµÝËÍÔÚÁÙ´²×ª»¯ÖеÄ×îÐÂÓ¦Óᣡ£¡£¡£¡£

ͼ5. ÓÃÓÚÖÎÁÆÓ¦ÓõŤ³ÌÍâÃÚÌåÀú³Ì¸ÅÊö
£¨4£©Ò½Ñ§ÃÀÈÝ
ÏÖÔÚҽѧÃÀÈݵķ½·¨ÓÐÐí¶à£¬£¬£¬£¬£¬ºÃ±Èͨ¹ý£º×¢Éä͸Ã÷ÖÊËáºÍÈâ¶¾¸Ë¾ú¶¾ÏòÀ´ÐÞ¸´Á³²¿ÐÎ̬ºÍ¹¦Ð§£¬£¬£¬£¬£¬µ«»á±£´æÒ»¶¨µÄ¸±×÷Ó㬣¬£¬£¬£¬ÈçÁ³²¿½©Ó²£¬£¬£¬£¬£¬ÒìÎï¸ÐÔöÌí¡£¡£¡£¡£¡£¶øÍâÃÚÌåÒÀ¸½ÆäÃâÒßÔÐԽϵ͡¢×éÖ¯´©Í¸Á¦½ÏÇ¿µÈÌØÕ÷£¬£¬£¬£¬£¬Öð½¥»ñµÃÒ½ÁÆÃÀÈÝÐÐÒµµÄ¹Ø×¢¡£¡£¡£¡£¡£ÏÖÔÚÍâÃÚÌåÔÚ¹¦Ð§ÐÔ»¤·ôºÍ¿¹Ë¥¡¢ÔÙÉúÐÞ¸´µÈÇáÒ½ÃÀÏîÄ¿ÖнÏΪ»ðÈÈ£¬£¬£¬£¬£¬¾ßÓмõС¼¡Áä¡¢¸ÄÉÆ·ôÖʺ͸ıä·ôÉ«µÈ×÷Óᣡ£¡£¡£¡£
ÍâÃÚÌåÄܹ»Ôö½ø³ÉÏËάϸ°ûµÄǨáãºÍÔöÖ³£¬£¬£¬£¬£¬ÖØÐ¼¤»î¼¡·ô×ÔÉíµÄÐÞ¸´»úÖÆ£¬£¬£¬£¬£¬»Ö¸´Òò×ÏÍâÏßÕÕÉä¶øïÔ̵ĵ¯ÐÔ×ðÁú¿Ê±ºÍÏËÁ¬×ðÁú¿Ê±£¬£¬£¬£¬£¬Í¬Ê±ÓÐÓÃïÔÌ×ÔÓÉ»ù£¨ROS£©µÄÌìÉú£¬£¬£¬£¬£¬´ÓȪԴÉϼõ»º¼¡·ôÀÏ»¯µÄ³ÌÐò¡£¡£¡£¡£¡£»£»£»£»£»£»¹¿ÉÒÔͨ¹ýÔö½ø½ºÔ×ðÁú¿Ê±µÄºÏ³ÉºÍÏËάϸ°ûµÄ»î»¯£¬£¬£¬£¬£¬ÍâÃÚÌå×¢ÉäÓÐÖúÓÚïÔÌÆ¤·ôÉϵÄÏ¸ÎÆºÍÖåÎÆ£¬£¬£¬£¬£¬Ê¹Æ¤·ôÔ½·¢½ôÖºÍÄêÇá¡£¡£¡£¡£¡£
ÔÚÎÄÏ×£ºExtracellular Vesicles in Facial Aesthetics: A ReviewÖУ¬£¬£¬£¬£¬×÷Õß×ܽáÁËϸ°ûÍâÄÒÅÝ£¨EV£© µÄ×îÐÂÑо¿£¬£¬£¬£¬£¬±¨¸æÁËÔÚÃæ²¿ÃÀѧÖеÄÓ¦Ó㬣¬£¬£¬£¬°üÀ¨È¥³ý°ÌºÛ¡¢Ã沿ÄêÇữ¡¢¿¹ÐàÂõºÍ¿¹É«ËØÀä¾²¡£¡£¡£¡£¡£»£»£»£»£»£»¹ÌÖÂÛÁË EV µÄ¸ß¼¶µÝËͲßÂÔ¡¢Ö²Îï EV µÄÖÎÁÆÇ±Á¦ÒÔ¼°Ê¹Óà EV ¸ÄÉÆÆ¤·ô״̬µÄÁÙ´²Ñо¿£¬£¬£¬£¬£¬EV ÁÆ·¨¿ÉÒÔïÔ̰̺ÛÐγɣ¬£¬£¬£¬£¬Ê¹ÀÏ»¯µÄƤ·ô»Ö¸´ÉúÁ¦£¬£¬£¬£¬£¬²¢ïÔÌÉ«ËØÀä¾²¡£¡£¡£¡£¡£ÕâЩÊÓ²ìЧ¹ûΪ»ùÓÚ EV µÄ»¯×±Æ·µÄ¿ª·¢ÌṩÁËÒÀ¾Ý¡£¡£¡£¡£¡£

ͼ6. ϸ°ûÍâÄÒÅݸÅÊö
£¨5£©ÔÙÉúҽѧ
ÍâÃÚÌåÔÚÔÙÉúҽѧÁìÓòÒ²Õ¹ÏÖ³öÆÕ±éÓ¦ÓÃÔ¶¾°¡£¡£¡£¡£¡£ËüÃǾßÓжàÖÖÔÙÉúÄÜÁ¦£¬£¬£¬£¬£¬°üÀ¨ÐÞ¸´×éÖ¯ËðÉË¡¢Ôö½øÑª¹ÜÌìÉú¡¢ÔöÇ¿ÃâÒß¹¦Ð§µÈ¡£¡£¡£¡£¡£ÀýÈ磬£¬£¬£¬£¬ÍâÃÚÌå¿ÉÔö½øÈí¹ÇÐÞ¸´ºÍÉú³¤£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆÈí¹ÇȱËðµÈ¹Ç¿Æ¼²²¡£¡£¡£¡£¡£»£»£»£»£»£»»¹¿Éͨ¹ý×ªÒÆÒªº¦×ðÁú¿Ê±ºÍϸ°ûÐźŷÖ×ÓÀ´Ôö½ø¸Îϸ°ûÉú³¤ºÍÐÞ¸´£¬£¬£¬£¬£¬½ø¶øÔÚ¸ÎËðÉËÖÎÁÆ·½ÃæÊ©Õ¹Ö÷Òª×÷Óᣡ£¡£¡£¡£
ɽ¶«´óѧ³ÂÀö£º´Ó¿¹¾úË®Äý½ºÊͷŵÄÌǹ¤³Ì»¯Ï¸°ûÍâÄÒÅÝͨ¹ýÔö½øÑª¹ÜÌìÉúÀ´¼ÓËÙÌÇÄò²¡ÉË¿ÚÓúºÏWang, K., et al. (2024). "Glycoengineered extracellular vesicles released from antibacterial hydrogel facilitate diabetic wound healing by promoting angiogenesis."
J Extracell Vesicles 13(11): e70013.IF=15.5
ÌÇÄò²¡ÉË¿ÚÓÉÓÚѪ¹ÜÌìÉúÊÜËðºÍÒ»Á¬Ñ¬È¾£¬£¬£¬£¬£¬ÒѳÉΪȫÇòҽѧÄÑÌâ¡£¡£¡£¡£¡£Ö»¹Üϸ°ûÍâÄÒÅÝ£¨EVs£©¿ÉÒÔ¸ÄÉÆÌÇÄò²¡É˿ڣ¬£¬£¬£¬£¬µ«Æä°ÐÏòÄÜÁ¦ÓÐÏÞ¡£¡£¡£¡£¡£¸ÃÑо¿Ì½ÌÖÁËÒ»ÖÖÐÂÐÍË®Äý½º·óÁÏÔÚÖÎÁÆÑ¬È¾ÐÔÌÇÄò²¡ÉË¿ÚÖеÄÌåÏÖ£¬£¬£¬£¬£¬¸ÃË®Äý½ºÓɼ׻ù±ûÏ©õ£»£»£»£»£»£»ùÃ÷½º¡¢Ìǹ¤³Ì»¯EVsºÍ¾ÛÀµ°±Ëá×é³É¡£¡£¡£¡£¡£¸ßͨÁ¿µ¥Ï¸°ûRNA²âÐò£¨scRNA-seq£©ºÍÃâÒßÓ«¹âȾɫÏÔʾ£¬£¬£¬£¬£¬ÌÇÄò²¡ÉË¿ÚÖÐE-Ñ¡ÔñËØ£¨SELE£©Ë®Æ½¸ßÓÚ·ÇÌÇÄò²¡É˿ڡ£¡£¡£¡£¡£¼ä³äÖÊ»ùÖÊϸ°û£¨MSCs£©Í¨¹ýº¬ÓÐÑÒÔåÌÇ»ù×ªÒÆÃ¸VII£¨FUT7£©ºÍCD63-P19-NlucÔØÌåµÄÂý²¡¶¾¾ÙÐÐתȾ£¬£¬£¬£¬£¬ÒÔÔöÇ¿ÑÜÉú×ÔתȾMSC£¨s-MSCs£©µÄEVs£¨s-EVs£©ÍâòE-Ñ¡ÔñËØÅäÌåÍÙÒºËữLewis X£¨sLeX£©µÄ±í´ï¡£¡£¡£¡£¡£ÔÚÖ¬¶àÌǴ̼¤Ï£¬£¬£¬£¬£¬s-EVs¿ÉÒÔ°ÐÏòÈËÆê¾²ÂöÄÚÆ¤Ï¸°û£¨HUVECs£©²¢ÔÚÌåÍâÔö½øÊܴ̼¤HUVECsµÄ¹¦Ð§¡£¡£¡£¡£¡£ÎªÁËÔö½øºÍÒ»Á¬ÊÍ·Ås-EVs£¬£¬£¬£¬£¬×÷ÕßÖÆ±¸ÁËÒ»ÖÖ¾ßÓÐÓÅÒ쿹¾úÄÜÁ¦¡¢ÉúÎïÏàÈÝÐԺͻúеÐÔÄܵļ׻ù±ûÏ©õ£»£»£»£»£»£»ùÃ÷½º£¨Gel£©/¾Û-L-Àµ°±Ëá¼×»ù±ûÏ©õ£»£»£»£»£»£»ù£¨PL£©-5Ë®Äý½º¡£¡£¡£¡£¡£ÔÚСÊóʵÑéÖУ¬£¬£¬£¬£¬s-EV@Gel/PL-5ÌåÏÖ³öÓÅÒìµÄѪ¹ÜÌìÉúºÍ¿¹Ñ×ÄÜÁ¦£¬£¬£¬£¬£¬²¢½øÒ»²½Ôö½øÁËѬȾÐÔÌÇÄò²¡É˿ڵÄÓúºÏ¡£¡£¡£¡£¡£Ñо¿Ð§¹ûչʾÁËs-EV@Gel/PL-5Ë®Äý½ºÔÚÁÙ´²ÖÎÁÆÌÇÄò²¡Ñ¬È¾ÐÔÉË¿ÚÖеÄDZÁ¦¡£¡£¡£¡£¡£

ͼ7. Ë®Äý½ºÔÚѬȾµÄÌÇÄò²¡ÉË¿ÚÉϵÄÓ¦ÓÃ
3¡¢Î´À´Éú³¤Ç÷ÊÆ
ÍâÃÚÌåËäÈ»Éú³¤Ô¶¾°ÁÉÀ«£¬£¬£¬£¬£¬¿ÉÊÇÒ²ÊÇÌôÕ½ºÍ»úÔµ²¢´æ£º
ÌôÕ½£ºÖ»¹ÜÍâÃÚÌåÔÚ¶à¸öÁìÓòÕ¹ÏÖ³öÖØ´óDZÁ¦£¬£¬£¬£¬£¬µ«ÏÖÔÚÈÔ±£´æÒ»ÏµÁÐÌôÕ½ºÍÎÊÌâ¡£¡£¡£¡£¡£ÀýÈ磬£¬£¬£¬£¬ÍâÃÚÌåµÄÎȹÌÐÔ¡¢´¿¶ÈºÍÖÊÁ¿µÈ·½ÃæµÄÎÊÌâÐèÒª½øÒ»²½Ñо¿Ï¢Õù¾ö£»£»£»£»£»£»±ðµÄ£¬£¬£¬£¬£¬ÍâÃÚÌåÔÚÔÙÉúҽѧÁìÓòµÄÓ¦Óû¹´¦ÓÚÑо¿½×¶Î£¬£¬£¬£¬£¬ÐèÒªÔÚÁÙ´²ÊÔÑéÖнøÒ»²½ÑéÖ¤ºÍÆÀ¹À¡£¡£¡£¡£¡£
»úÔµ£ºËæ×ŶÔÍâÃÚÌåÑо¿µÄÒ»Ö±ÉîÈëºÍ¼¼ÊõµÄһֱǰ½ø£¬£¬£¬£¬£¬ÍâÃÚÌåÓÐÍûÔÚ¸ü¶àÁìÓò»ñµÃÓ¦ÓúÍÍÆ¹ã¡£¡£¡£¡£¡£ÀýÈ磬£¬£¬£¬£¬ÔÚ°©Ö¢ÖÎÁÆ·½Ã棬£¬£¬£¬£¬Í¨¹ýÍâÔ´ÐÔĬȻ»ò¼¤»îÍâÃÚÌåmiRNA¿ÉÄÜΪ°©Ö¢ÖÎÁÆÌṩÐÂ;¾¶£»£»£»£»£»£»ÔÚ×ÔÉíÃâÒßÐÔ¼²²¡ÖÎÁÆ·½Ã棬£¬£¬£¬£¬ÍâÃÚÌåÒòÆäÔö½øÏ¸°ûÔöÖ³ºÍ·Ö½âµÄÄÜÁ¦¶ø±¸ÊܹØ×¢£»£»£»£»£»£»±ðµÄ£¬£¬£¬£¬£¬ÔÚÉñ¾ÍËÐÐÐÔ¼²²¡ÖÎÁƵȷ½Ã棬£¬£¬£¬£¬ÍâÃÚÌåÒ²Õ¹ÏÖ³öÖØ´óDZÁ¦¡£¡£¡£¡£¡£
ÍâÃÚÌåÖ®ÒÔÊǻ𱬣¬£¬£¬£¬£¬Ö÷ÒªµÃÒæÓÚÆäÔÚ»ù´¡Ñо¿¡¢ÁÙ´²Ó¦ÓÃÔ¶¾°¡¢Êг¡ÓëÉú³¤Ç÷ÊÆÒÔ¼°ÌôÕ½Óë»úÔµµÈ·½ÃæµÄ×ÛºÏÌåÏÖ¡£¡£¡£¡£¡£Î´À´£¬£¬£¬£¬£¬Ëæ×ŶÔÍâÃÚÌåÉúÎïȪԴ¡¢ÎïÖÊ×é³É¼°ÔËÊä»úÖÆµÈÑо¿µÄÉîÈ룬£¬£¬£¬£¬ÒÔ¼°ÍâÃÚÌåÔÚ¼²²¡Õï¶Ï¡¢Ò©ÎïµÝËͺÍÔÙÉúҽѧµÈÁìÓòÓ¦ÓõÄÒ»Ö±ÍØÕ¹£¬£¬£¬£¬£¬ÍâÃÚÌåÓÐÍûÔÚ¸ü¶àÁìÓòʩչÖ÷Òª×÷Óò¢ÎªÈËÀ࿵½¡ÊÂÒµ×ö³ö¸ü´óТ˳¡£¡£¡£¡£¡£
×îж¯Ì¬
-
02.26
תȾsiRNAÃØóÅ£º¸ßЧʵÑéÀֳɵÄÒªº¦°ì·¨ÆÊÎö
-
01.25
¿ÆÑÐÈ˱ØÐèÕÆÎÕ¹¹½¨ÔØÌåµÄÒªÁ죺³¬ÏêÏ¸ÔØÌå¹¹½¨¼Æ»®
-
01.24
2024Äê¶È½ð¿ªÈðÉúÎïÖúÁ¦225ƪ¸ß·ÖÎÄÏ׵ĽÒÏþ
-
01.15
¸É»õ·ÖÏí | ÔõÑù¿ìËÙ¸ßЧµÄÉè¼ÆsiRNA£¿£¿£¿
-
01.13
Ö²ÎïÍâÃÚÌå-ÏÂÒ»´úÉúÎïÖÎÁƼ¼ÊõÐÂÐÇ£¿£¿£¿
-
01.10
¸ß·ÖÇ°ÑØÎÄÏ×½â¶Á - Éî¶ÈÆÊÎöÍâÃÚÌå
-
01.08
ÍâÃÚÌåÑо¿±£Ä·¼¶¹¥ÂÔ |Ò»ÎÄ´øÄã½âËøÍâÃÚÌå×îпÆÑÐ˼Ð÷
-
01.07
ÉúÎï½ç¿¸°Ñ×Ó-ÍâÃÚÌåËÞÊÀ½ñÉú¼°Ó¦ÓÃÔ¶¾°
-
01.06
¡¾¸É»õ¡¿Ë«Ó«¹âËØÃ¸ÊµÑéÀÏʧ°Ü£¬£¬£¬£¬£¬ÕâЩϸ½ÚÄãgetµ½ÁËÂ𣿣¿£¿
-
12.03
¡¾¸É»õ¡¿È«·½Î»ÆÊÎöGST Pull-downʵÑé
- ɨÂëµÇÈë
- ÕË»§ÃÜÂëµÇÈë
- ¶ÌÐÅÑéÖ¤µÇÈë
ÐëÖª
Ê×´Î΢ÐÅɨÂëÓû§°ì·¨£º
1.΢ÐÅɨÂë¡£¡£¡£¡£¡£
2.±¾Ò³ÃæÍêÉÆÊÖ»úÑéÖ¤¡£¡£¡£¡£¡£
-
ÔÚÏ߿ͷþ -
ÔÚÏß¶©¹º -
ɨÂëÁì×ÊÁÏɨÂëÁì×ÊÁÏ
µç»°£º027-87960366
-
ÎÄÏ×½±ÀøÉêÇë
×ðÁú¿Ê±
